title: Extended high dose letrozole regimen versus short low dose letrozole regimen as an adjuvant to gonadotropin releasing hormone antagonist protocol in poor responders undergoing IVF-ET.
abstract: OBJECTIVE
  To compare the efficacy and cost-effectiveness of extended high dose letrozole regimen/HPuFSH-gonadotropin releasing hormone antagonist (GnRHant) protocol with short low dose letrozole regimen/HPuFSH-GnRHant protocol in poor responders undergoing IVF-ET.
  
  
  METHODS
  In this randomized controlled trial, 136 women who responded poorly to GnRH agonist long protocol in their first IVF cycle were randomized into two equal groups using computer generated list and were treated in the second IVF cycle by either extended letrozole regimen (5 mg/day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days) combined with HPuFSH-GnRHant protocol or short letrozole regimen (2.5 mg/day from cycle day 3-7) combined with HPuFSH-GnRHant protocol.
  
  
  RESULTS
  There were no significant differences between both groups with regard to number of oocytes retrieved and clinical pregnancy rate (5.39 ± 2.08 vs. 5.20 ± 1.88 and 22.06% vs. 16.18%, respectively).The total gonadotropins dose and medications cost per cycle were significantly lower in extended letrozole group (44.87 ± 9.16 vs. 59.97 ± 14.91 ampoules and 616.52 ± 94.97 vs. 746.84 ± 149.21 US Dollars ($), respectively).The cost-effectiveness ratio was 2794 $ in extended letrozole group and 4616 $ in short letrozole group.
  
  
  CONCLUSIONS
  Extended letrozole regimen/HPuFSH-GnRHant protocol was more cost-effective than short letrozole regimen/HPuFSH-GnRHant protocol in poor responders undergoing IVF-ET.
authors.affiliation: Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Cairo, Egypt. umfrfouda@yahoo.com
authors.forename: Usama M
authors.initials: UM
authors.lastname: Fouda
authors.forename: Ahmed M
authors.initials: AM
authors.lastname: Sayed
mesh_terms: D000277:Adjuvants, Pharmaceutic / Q000008:administration & dosage / Q000191:economics; D000328:Adult; D003362:Cost-Benefit Analysis; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004351:Drug Resistance / Q000187:drug effects; D004624:Embryo Transfer / Q000379:methods*; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage / Q000191:economics; D005307:Fertilization in Vitro / Q000379:methods*; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D006727:Hormone Antagonists / Q000008:administration & dosage* / Q000191:economics; D006801:Humans; D000077289:Letrozole; D008297:Male; D009570:Nitriles / Q000008:administration & dosage* / Q000191:economics; D010062:Ovulation Induction / Q000191:economics / Q000379:methods*; D011247:Pregnancy; D018873:Pregnancy Rate; D017211:Treatment Failure; D014230:Triazoles / Q000008:administration & dosage* / Q000191:economics
chemical_list: D000277:Adjuvants, Pharmaceutic; D005300:Fertility Agents, Female; D006727:Hormone Antagonists; D009570:Nitriles; D014230:Triazoles; D007987:Gonadotropin-Releasing Hormone; D000077289:Letrozole